Table 2.

Risk of Fracture, Overall and by Type, by Treatment Group

	Pioglitazone (n = 1939)			Placebo (n = 1937)			Risk ∆ (%)c	HR (95% CI)
	Fractures	Ptsa	Risk (%)b	Fractures	Ptsa	Risk (%)b
Any fracture	376	218	13.6	225	145	8.8	4.9	1.53 (1.24–1.89)
Energy
Low energy	295	178	11.2	184	119	7.2	4.0	1.51 (1.20–1.91)
High energy	67	35	2.1	31	22	1.3	0.8	1.60 (0.94–2.73)
Unknown	14	14	0.9	10	8	0.5	0.5	1.86 (0.74–4.66)
Stress
Nonstress	353	204	12.8	204	137	8.3	4.5	1.51 (1.22–1.88)
Stress	15	10	0.6	14	8	0.6	0.0	1.25 (0.49–3.17)
Unknown	8	8	0.5	7	6	0.4	0.1	1.40 (0.44–4.41)
Pathology
Nonpathologic	371	215	13.4	214	141	8.6	4.9	1.55 (1.26–1.92)
Pathologic	3	3	0.2	6	3	0.2	0.0	1.00 (0.20–4.96)
Unknown	2	2	0.1	5	4	0.2	−0.1	0.50 (0.09–2.72)
Serious/nonseriousd
Serious	178	99	6.2	99	62	3.7	2.4	1.61 (1.17–2.21)
Nonserious	190	128	8.2	123	92	5.6	2.6	1.41 (1.07–1.84)
Unknown	8	6	0.4	3	2	0.1	0.3	3.00 (0.61–14.89)
Low energy, nonpathologice	292	176	11.1	178	118	7.2	3.9	1.51 (1.19–1.90)
Serious, low energy, nonpathologicd,e	127	76	4.7	83	52	3.1	1.6	1.47 (1.03–2.09)

^aNumber of participants with fracture.

^bFracture risk at 5 years from Kaplan–Meier life table.

^cRD at 5 years from Kaplan–Meier life table.

^dFracture considered serious if surgery, procedure, or hospitalization required.

^eRestricted fracture is defined as low-energy and nonpathologic fracture.